Abstract:The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg cells, dendritic, myeloid and monocytic sub-populations in the tumor microenvironment acts to calibrate the immune response to malignant cells. Accumulating evidence is pointing to a role for B cells in modulating the immune response to both solid tumors and hematologic cancer. Evidence from murine autoimmune models has defined B regulatory cell (Breg) subsets that express cytokines such as IL-10, TGF-β, and/or express immune regulatory ligands such as PD-L1, which can suppress T cell and/or natural killer cell responses. Multiple murine tumor models exhibit decreased tumor growth in B cell deficient or B cell depleted mice. In several of these models, B cells inhibit T cell mediated tumor immunity and/or facilitate conversion of T cells to CD4+CD25+FoxP3+ T regs, which act to attenuate the innate and/or adaptive antitumor immune response.Mechanisms of suppression include the acquisition of inhibitory ligand expression, and phosphorylation of Stat3, and induction of IL-10 and TGF-β, resulting in a Breg phenotype. Breg suppressive activity may affect diverse cell subtypes, including T effector cells, NK cells, myeloid derived suppressor cells (MDSC) and/or tumor associated macrophages. B cells may also directly promote tumorigenesis through recruitment of inflammatory cells, and upregulation of pro-angiogenic genes and pro-metastatic collagenases.Breg infiltration has now been identified in a variety of solid tumor malignancies including but not limited to ovarian, gastric, non-small cell lung cancer, pancreatic, esophageal, head and neck, and hepatocellular carcinomas. Increasing evidence suggests that recruitment of B cells and acquisition of suppressive activity within the tumor bed may be an important mechanism through which B cells may modulate innate and/or adaptive anti-tumor immunity. B cell depletion in the clinic using anti-CD20 antibodies and/or inhibitors of BTK and/or other signaling pathways, may be a useful strategy for augmenting the anti-tumor immune response.

T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion

Soluble and Membrane-Bound TGF-β-Mediated Regulation of Intratumoral T Cell Differentiation and Function in B-Cell Non-Hodgkin Lymphoma

IL-10 Induces the Development of Immunosuppressive CD14 + HLA-DR Low/− Monocytes in B-cell Non-Hodgkin Lymphoma

Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications

B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974?

[CD4+ CD25high Regulatory T Cells in Peripheral Blood of Patients with B Cell Non-Hodgkin's Lymphoma].

Neglected no more: B cell-mediated anti-tumor immunity

B cell regulation of the anti-tumor response and role in carcinogenesis

Mechanism of cytotoxicity mediated by autologous tumour-specific CD4~+ T-cell clones against B-cell non-Hodgkin's lymphoma

The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate

Cytotoxic CD4~+ T clones as effector cells in B cell non-Hodgkin's lymphoma

Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma

Gene regulatory mechanisms of T cell exhaustion in diffuse large B cell lymphoma based on single-cell transcriptome data

Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment

The challenge of the microenvironment in B-cell lymphomas

CTLA-4 Limits Anti-Cd20-mediated Tumor Regression

BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion

T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications

Clinical significance of T-regulatory cells in B-cell non-Hodgkin's lymphoma

T Cell Anergy, Exhaustion, Senescence, and Stemness in the Tumor Microenvironment

T Cell Exhaustion Characterized by Compromised MHC Class I and II Restricted Cytotoxic Activity Associates with Acute B Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.